Mantle Cell Lymphoma Therapeutics Market Growth Trajectory Through 2024-2033

Spread the love

The Mantle Cell Lymphoma Therapeutics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Mantle Cell Lymphoma Therapeutics Market:

https://www.thebusinessresearchcompany.com/report/mantle-cell-lymphoma-therapeutics-global-market-report

According to The Business Research Company’s Mantle Cell Lymphoma Therapeutics Global Market Report 2024, The mantle cell lymphoma therapeutics market size has grown strongly in recent years. It will grow from $2.26 billion in 2023 to $2.45 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to advances in research, clinical trial success, improved diagnostic tools, treatment access expansion, collaborative research initiatives..

The mantle cell lymphoma therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.29 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to targeted therapies advancements, immunotherapy innovations, personalized medicine trends, global market expansion, increasing incidence rates.. Major trends in the forecast period include immunotherapy advancements, precision medicine and biomarker development, targeted therapies for specific pathways, combination therapies, integration of artificial intelligence (ai)..

The rise in the prevalence of mantle cell lymphoma is expected to propel the growth of the mantle cell lymphoma therapeutics market going forward. Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL), a cancer affecting the lymphatic system. Mantle Cell Lymphoma therapeutics help reduce the disease’s prevalence by treating and managing the condition and improving patient outcomes, prolonged survival, and reduced disease burden. For instance, in December 2022, according to the National Library of Medicine, a US-based biomedical library operated by the United States Federal Government, the annual incidence of mantle cell lymphoma is one case per 200,000 people, contributing to 5% of all non-Hodgkins lymphomas. Therefore, the rise in the prevalence of mantle cell lymphoma is driving the growth of the mantle cell lymphoma therapeutics market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=10813&type=smp

The mantle cell lymphoma therapeutics market covered in this report is segmented –

1) By Type: Combination Therapy, Monotherapy

2) By Mechanism of Action: Bruton Tyrosine Kinase Inhibitors, Alkylating Agents, Deoxyribonucleic Acid Synthesis Inhibitors, Microtubule Inhibitors, Monoclonal Antibodies, Other Mechanisms

3) By Route of Administration: Oral, Parenteral

4) By Application: Hospital, Research Institute, Other Applications

The development of targeted therapy drugs is a key trend gaining popularity in the mantle cell lymphoma therapeutics market. Major companies operating in the mantle cell lymphoma therapeutics market are developing new drugs for targeted therapy to sustain their position in the market. For instance, in March 2023, AstraZeneca plc., a UK-based pharmaceutical company, received approval for Calquence (acalabrutinib) from National Medical Products Administration (NMPA) to market the drug in China for adult patients who have mantle cell lymphoma (MCL). Calquence (acalabrutinib) is a selective Bruton’s tyrosine kinase (BTK) inhibitor, and it is used to offer a tolerable and effective new treatment option to help control mantle cell lymphoma.

The mantle cell lymphoma therapeutics market report table of contents includes: